The effects of sunitinib and pazopanib are potentially depending on different factors such as VEGFR activity, and range from disease stability to partial response in (metastatic) renal cell carcinomas and (metastatic) pancreatic neuroendocrine tumors.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}